BiotechTube
Home/AmMax Bio/Kirk Johnson, PhD
KJ

Kirk Johnson, PhD

Chief Scientific Officer

AmMax Bio

Therapeutic Areas

Oncology

AmMax Bio Pipeline

DrugIndicationPhase
AMB-066Colorectal cancer with Minimal residual disease (CRC MRD)Phase 2
AMB-104AML and solid tumorsDiscovery
AMB-051Tenosynovial giant cell tumor (TGCT)Discovery

Leadership Team at AmMax Bio

LH
Larry Hsu, PhD
Chief Executive Officer
LZ
Laura Zhu, PhD, MBA
Chief Business Officer
DN
Dorothy Nguyen, MD
VP, Clinical Development
LA
Laman Alani, PhD
SVP of Product Development
AS
Andrew Sauter
Chief Financial Officer
View full AmMax Bio profile